Acrux Ltd (ARUXF) 0.5265 $ARUXF
Female Sexual Dysfunction Global Clinical Trials Review, H2, 2015 - Key Vendors: Allergan Plc, ANI Pharmaceuticals, Inc. & Palatin Technologies, Inc.
M2 - Mon Jan 18, 5:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/s2x472/female_sexual) has announced the addition of the "Female Sexual Dysfunction Global Clinical Trials Review, H2, 2015" report to their offering. Our clinical trial report, Female Sexual Dysfunction Global Clinical Trials Review, H2, 2015" provides an overview of Female Sexual Dysfunction clinical trials scenario. This report provides top line data relating to the clinical trials on Female Sexual Dysfunction. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials Companies Mentioned: - Emotional Brain BV - Sprout Pharmaceuticals, Inc. - Pfizer Inc. - Allergan Plc - ANI Pharmaceuticals, Inc. - Vivus, Inc. - Strategic Sciences and Technologies, LLC - Palatin Technologies, Inc. - Acrux Limited - Apricus Biosciences, Inc. For more information visit http://www.researchandmarkets.com/research/s2...ale_sexual
AGN: 246.96 (-0.16), ANIP: 54.57 (-1.58), PFE: 34.69 (-0.18), PTN: 0.50 (+0.01), APRI: 0.44 (unch)
Testosterone Replacement Therapy (TRT) - Global Strategic Business Report 2015: Easy-to-use Formulations - A Major Boost to TRT Market
M2 - Tue Mar 31, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zhhxcs/testosterone) has announced the addition of the "Testosterone Replacement Therapy (TRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The Global and the US markets are analyzed by the following Product Segments: Topicals, Patches, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 35 companies including many key and niche players such as: - AbbVie, Inc. (US) - Acrux Limited (Australia) - Actavis, Inc. (US) - Antares Pharma, Inc. (US) - Auxilium Pharmaceuticals, Inc. (US) - Bayer HealthCare Pharmaceuticals (Germany) - Columbia Laboratories, Inc. (US) - Eli Lilly and Company (US) - Endo Pharmaceuticals Inc. (US) - ProStrakan Group PLC. (UK) - Trimel Pharmaceutical Corporation (Canada) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. GROWTH DRIVERS AND MARKET TRENDS 3. COMPETITION 4. AN OVERVIEW OF SELECT DRUGS ON THE MARKET 5. TESTOSTERONE DEFICIENCY AND TRT - AN OVERVIEW 6. PRODUCT LAUNCHES/APPROVALS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 35 (including Divisions/Subsidiaries - 36) - The United States (21) - Canada (3) - Japan (1) - Europe (
- - Germany (1) - - The United Kingdom (4) - - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (3) For more information visit http://www.researchandmarkets.com/research/zh...stosterone
ENDP: 17.59 (+0.15), ACT: 298.98 (-2.94), AUXL: 36.47 (-0.06), LLY: 75.12 (-0.34), ABBV: 65.00 (-0.09), CBRX: 7.36 (+0.45), ATRS: 1.14 (+0.02)
Female Sexual Dysfunction Global Clinical Trials Review, H2, 2015 - Key Vendors: Allergan Plc, ANI Pharmaceuticals, Inc. & Palatin Technologies, Inc.
M2 - Mon Jan 18, 5:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/s2x472/female_sexual) has announced the addition of the "Female Sexual Dysfunction Global Clinical Trials Review, H2, 2015" report to their offering. Our clinical trial report, Female Sexual Dysfunction Global Clinical Trials Review, H2, 2015" provides an overview of Female Sexual Dysfunction clinical trials scenario. This report provides top line data relating to the clinical trials on Female Sexual Dysfunction. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials Companies Mentioned: - Emotional Brain BV - Sprout Pharmaceuticals, Inc. - Pfizer Inc. - Allergan Plc - ANI Pharmaceuticals, Inc. - Vivus, Inc. - Strategic Sciences and Technologies, LLC - Palatin Technologies, Inc. - Acrux Limited - Apricus Biosciences, Inc. For more information visit http://www.researchandmarkets.com/research/s2...ale_sexual
AGN: 246.96 (-0.16), ANIP: 54.57 (-1.58), PFE: 34.69 (-0.18), PTN: 0.50 (+0.01), APRI: 0.44 (unch)
Testosterone Replacement Therapy (TRT) - Global Strategic Business Report 2015: Easy-to-use Formulations - A Major Boost to TRT Market
M2 - Tue Mar 31, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zhhxcs/testosterone) has announced the addition of the "Testosterone Replacement Therapy (TRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The Global and the US markets are analyzed by the following Product Segments: Topicals, Patches, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 35 companies including many key and niche players such as: - AbbVie, Inc. (US) - Acrux Limited (Australia) - Actavis, Inc. (US) - Antares Pharma, Inc. (US) - Auxilium Pharmaceuticals, Inc. (US) - Bayer HealthCare Pharmaceuticals (Germany) - Columbia Laboratories, Inc. (US) - Eli Lilly and Company (US) - Endo Pharmaceuticals Inc. (US) - ProStrakan Group PLC. (UK) - Trimel Pharmaceutical Corporation (Canada) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. GROWTH DRIVERS AND MARKET TRENDS 3. COMPETITION 4. AN OVERVIEW OF SELECT DRUGS ON THE MARKET 5. TESTOSTERONE DEFICIENCY AND TRT - AN OVERVIEW 6. PRODUCT LAUNCHES/APPROVALS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 35 (including Divisions/Subsidiaries - 36) - The United States (21) - Canada (3) - Japan (1) - Europe (
- - Germany (1) - - The United Kingdom (4) - - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (3) For more information visit http://www.researchandmarkets.com/research/zh...stosterone ENDP: 17.59 (+0.15), ACT: 298.98 (-2.94), AUXL: 36.47 (-0.06), LLY: 75.12 (-0.34), ABBV: 65.00 (-0.09), CBRX: 7.36 (+0.45), ATRS: 1.14 (+0.02)
